MedTrace Logo

Demineralized Dentin Matrix Versus Mineralized Plasmatic Matrix on Alveolar Ridge Preservation in Molar Extraction Sites

NCT07239193 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-11-20

No results posted yet for this study

Summary

When a tooth is removed, the bone around it (called the alveolar ridge) naturally shrinks. This study compares two bone grafting materials to find out which one better preserves bone after molar extraction:

Demineralized Dentin Matrix (DDM): A material made from the patient's own extracted tooth, treated to remove minerals while keeping bone-forming proteins.

Mineralized Plasmatic Matrix (MPM): A mixture of a standard bone substitute and platelet-rich plasma from the patient's blood.

Conditions

  • Socket Preservation
  • Alveolar Ridge Preservation

Interventions

BIOLOGICAL

Demineralized Dentin Matrix (DDM) + Platelet-Rich Fibrin (PRF)

Autogenous dentin-derived grafting material is used as a bone substitute for alveolar ridge preservation following molar extraction. PRF, obtained from the patient's centrifuged blood, is mixed with DDM to enhance graft stability and promote healing.

BIOLOGICAL

Mineralized Plasmatic Matrix (MPM)

A xenogenic bone substitute is mixed with autologous platelet-rich plasma to form a mineralized plasmatic matrix, which serves as a control graft for ridge preservation after molar extraction.

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • Tarek Ibrahim ElGhareeb, Phd · Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Cairo University

  • Salah Eldin ElAbbasy, Phd · Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Cairo University

  • Ahmed Suliman Ahmed, Bds · Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Cairo University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-01
Primary Completion
2026-07-01
Completion
2026-11-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07239193 on ClinicalTrials.gov